nach oben

Erschienen in:

05.08.2023 | Epidemiology

Increases in BMI contribute to worsening inflammatory biomarkers related to breast cancer risk in women: a longitudinal study

verfasst von: Yu Hao, Jinyu Xiao, Ping Fu, Lanping Yan, Xunying Zhao, Xueyao Wu, Min Zhou, Xiaofan Zhang, Bin Xu, Xingyue Li, Zhenmi Liu, Chunxia Yang, Xin Wang, Lu Long, Xia Jiang, Jiaqiang Liao, Ben Zhang, Jiayuan Li

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Inflammatory adipokines and cytokines play a pivotal role in linking obesity and breast cancer (BC) risk in women. We investigated the longitudinal associations between BMI change and trajectories of inflammatory biomarkers related to BC risk.

Methods

A longitudinal study was conducted among 442 Chinese women with 3-year repeated measures from 2019 to 2021. Plasma circulating inflammatory biomarkers related to BC risk, including adiponectin (ADP), resistin (RETN), soluble leptin receptor (sOB-R), insulin-like growth factor-binding protein-3 (IGFBP-3), and C-reactive protein (CRP), were examined annually. Linear mixed-effect models (LMM) were applied to investigate associations of time-varying BMI with trajectories of biomarkers. We additionally examined the modification effect of baseline BMI groups, menopausal status, and metabolic syndrome.

Results

BMI was associated with increased levels of RETN, CRP, sOB-R, and decreased levels of ADP at baseline. An increasing BMI rate was significantly associated with an average 3-year increase in RETN (β = 0.019, 95% CI 0.004 to 0.034) and sOB-R (β = 0.022, 95% CI 0.009 to 0.035), as well as a decrease in ADP (β = − 0.006, 95% CI − 0.012 to 0.001). These associations persisted across different baseline BMI groups. An increasing BMI rate was significantly associated with an average 3-year increase in CRP levels among normal weight (β = 0.045, 95% CI 0.001 to 0.088) and overweight (β = 0.060, 95% CI 0.014 to 0.107) women. As BMI increased over time, a more remarkable decrease in ADP was observed among women with metabolic syndrome (β = − 0.016, 95% CI − 0.029 to − 0.004) than those without metabolic syndrome at baseline.

Conclusions

A higher increase rate of BMI was associated with poorer trajectories of inflammatory biomarkers related to BC risk. Recommendations for BMI reduction may benefit BC prevention in women, particularly for those with metabolic syndrome.

Nur mit Berechtigung zugänglich

Sung H, Siegel RL, Torre LA et al (2019) Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin 69(2):88–112. https://doi.org/10.3322/caac.21499CrossRefPubMed

Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M (2018) Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol 6(6):e6–e15. https://doi.org/10.1016/S2213-8587(18)30150-5CrossRefPubMedPubMedCentral

Amadou A, Ferrari P, Muwonge R et al (2013) Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obes Rev 14(8):665–678. https://doi.org/10.1111/obr.12028CrossRefPubMed

World Cancer Research Fund/American Institute for Cancer Research (2018) Continuous Update Project Report 2018. Body fatness and weight gain and the risk of cancer. World Cancer Research Fund International, London. https://www.wcrf.org/wp-content/uploads/2021/01/Body-fatness-and-weight-gain_0.pdf. Accessed 1 Oct 2022

Gunter MJ, Wang T, Cushman M et al (2015) Circulating adipokines and inflammatory markers and postmenopausal breast cancer risk. J Natl Cancer Inst (JNCI) 107(9):djv69. https://doi.org/10.1093/jnci/djv169CrossRef

Christodoulatos GS, Spyrou N, Kadillari J, Psallida S, Dalamaga M (2019) The role of adipokines in breast cancer: current evidence and perspectives. Curr Obes Rep 8(4):413–433. https://doi.org/10.1007/s13679-019-00364-yCrossRefPubMed

Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11(2):85–97. https://doi.org/10.1038/nri2921CrossRefPubMedPubMedCentral

Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6(10):772–783. https://doi.org/10.1038/nri1937CrossRefPubMed

Rosen ED, Spiegelman BM (2006) Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444(7121):847–853. https://doi.org/10.1038/nature05483CrossRefPubMedPubMedCentral

10.

Booth A, Magnuson A, Fouts J, Foster M (2015) Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig 21(1):57–74. https://doi.org/10.1515/hmbci-2014-0037CrossRefPubMed

11.

Assiri AMA, Kamel HFM (2016) Evaluation of diagnostic and predictive value of serum adipokines: leptin, resistin and visfatin in postmenopausal breast cancer. Obes Res Clin Pract 10(4):442–453. https://doi.org/10.1016/j.orcp.2015.08.017CrossRefPubMed

12.

Dalamaga M, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E, Lekka A (2013) Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem 46(7–8):584–590. https://doi.org/10.1016/j.clinbiochem.2013.01.001CrossRefPubMed

13.

Santillán-Benítez JG, Mendieta-Zerón H, Gómez-Oliván LM et al (2013) The tetrad BMI, leptin, leptin/adiponectin (L/A) ratio and CA 15–3 are reliable biomarkers of breast cancer. J Clin Lab Anal 27(1):12–20. https://doi.org/10.1002/jcla.21555CrossRefPubMedPubMedCentral

14.

Aksoy T, Trabulus DC, Aral H, Serin E, Kelten TC (2020) Significantly lower serum adiponectin levels in the postmenopausal age may be specific for breast cancer risk. Istanb Med J 21(5):355–361. https://doi.org/10.4274/imj.galenos.2020.92979CrossRef

15.

Diao S, Wu X, Zhang X et al (2021) Obesity-related proteins score as a potential marker of breast cancer risk. Sci Rep 11(1):8230. https://doi.org/10.1038/s41598-021-87583-3CrossRefPubMedPubMedCentral

16.

Neuhouser Marian L, Aragaki AK, Prentice RL et al (2015) Overweight, obesity and postmenopausal invasive breast cancer risk. JAMA Oncol 1(5):611–621. https://doi.org/10.1001/jamaoncol.2015.1546CrossRefPubMedPubMedCentral

17.

Byers T, Sedjo RL (2011) Does intentional weight loss reduce cancer risk? Diabetes Obes Metab 13(12):1063–1072. https://doi.org/10.1111/j.1463-1326.2011.01464.xCrossRefPubMed

18.

King B, Jiang Y, Su X et al (2013) Weight control, endocrine hormones and cancer prevention. Exp Biol Med (Maywood, NJ) 238(5):502–508. https://doi.org/10.1177/1535370213480695CrossRef

19.

Foula WH, Emara RH, Eldeeb MK, Mokhtar SA, El-Sahn FA (2020) Effect of a weight loss program on serum adiponectin and insulin resistance among overweight and obese premenopausal females. J Egypt Public Health Assoc 95(1):32. https://doi.org/10.1186/s42506-020-00060-zCrossRefPubMedPubMedCentral

20.

Linkov F, Maxwell GL, Felix AS et al (2012) Longitudinal evaluation of cancer-associated biomarkers before and after weight loss in RENEW study participants: implications for cancer risk reduction. Gynecol Oncol 125(1):114–119. https://doi.org/10.1016/j.ygyno.2011.12.439CrossRefPubMed

21.

van Gemert WA, May AM, Schuit AJ, Oosterhof BYM, Peeters PH, Monninkhof EM (2016) Effect of weight loss with or without exercise on inflammatory markers and adipokines in postmenopausal women: the SHAPE-2 trial, a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 25(5):799–806. https://doi.org/10.1158/1055-9965.EPI-15-1065CrossRefPubMed

22.

Ambeba EJ, Styn MA, Kuller LH, Brooks MM, Evans RW, Burke LE (2013) Longitudinal effects of weight loss and regain on cytokine concentration of obese adults. Metabolism 62(9):1218–1222. https://doi.org/10.1016/j.metabol.2013.04.004CrossRefPubMedPubMedCentral

23.

Herrick JE, Panza GS, Gollie JM (2016) Leptin soluble receptor, and the free leptin index following a diet and physical activity lifestyle intervention in obese males and females. J Obes 2016:e8375828. https://doi.org/10.1155/2016/8375828CrossRef

24.

Blüher M, Rudich A, Klöting N et al (2012) Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care 35(2):342–349. https://doi.org/10.2337/dc11-1267CrossRefPubMedPubMedCentral

25.

World Health Organization (2000) The Asia-Pacific perspective: redefining obesity and its treatment. Health Communications, Sydney. https://apps.who.int/iris/bitstream/handle/10665/206936/0957708211_eng.pdf. Accessed 11 Sept 2022

26.

Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735–2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404CrossRefPubMed

27.

Karra P, Winn M, Pauleck S et al (2022) Metabolic dysfunction and obesity-related cancer: beyond obesity and metabolic syndrome. Obesity (Silver Spring) 30(7):1323–1334. https://doi.org/10.1002/oby.23444CrossRefPubMed

28.

Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (2012) Metabolic syndrome and risk of cancer. Diabetes Care 35(11):2402–2411. https://doi.org/10.2337/dc12-0336CrossRefPubMedPubMedCentral

29.

Wu X, Zhang X, Hao Y, Li J (2021) Obesity-related protein biomarkers for predicting breast cancer risk: an overview of systematic reviews. Breast Cancer (Tokyo, Jpn) 28(1):25–39. https://doi.org/10.1007/s12282-020-01182-0CrossRef

30.

Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115(5):911–919. https://doi.org/10.1016/j.jaci.2005.02.023CrossRefPubMed

31.

Steppan CM, Bailey ST, Bhat S et al (2001) The hormone resistin links obesity to diabetes. Nature 409(6818):307–312. https://doi.org/10.1038/35053000CrossRefPubMed

32.

Deb A, Deshmukh B, Ramteke P, Bhati FK, Bhat MK (2021) Resistin: a journey from metabolism to cancer. Transl Oncol 14(10):101178. https://doi.org/10.1016/j.tranon.2021.101178CrossRefPubMedPubMedCentral

33.

Schaab M, Kratzsch J (2015) The soluble leptin receptor. Best Pract Res Clin Endocrinol Metab 29(5):661–670. https://doi.org/10.1016/j.beem.2015.08.002CrossRefPubMed

34.

Baxter RC (2014) IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer 14(5):329–341. https://doi.org/10.1038/nrc3720CrossRefPubMed

35.

Jiang X, Shapiro DJ (2014) The immune system and inflammation in breast cancer. Mol Cell Endocrinol 382(1):673–682. https://doi.org/10.1016/j.mce.2013.06.003CrossRefPubMed

36.

Cruz-Mejía S, Durán López HH, Navarro Meza M, Xochihua Rosas I, de la Peña S, Arroyo-Helguera OE (2018) Body mass index is associated with interleukin-1, adiponectin, oxidative stress and ioduria levels in healthy adults. Nutr Hosp 35(4):841–846. https://doi.org/10.20960/nh.1614CrossRefPubMed

37.

Cohen SS, Gammon MD, Signorello LB et al (2011) Serum adiponectin in relation to body mass index and other correlates in black and white women. Ann Epidemiol 21(2):86–94. https://doi.org/10.1016/j.annepidem.2010.10.011CrossRefPubMed

38.

Nieva-Vazquez A, Pérez-Fuentes R, Torres-Rasgado E, López-López JG, Romero JR (2014) Serum resistin levels are associated with adiposity and insulin sensitivity in obese hispanic subjects. Metab Syndr Relat Disord 12(2):143–148. https://doi.org/10.1089/met.2013.0118CrossRefPubMedPubMedCentral

39.

Chen BH, Song Y, Ding EL et al (2009) Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 32(2):329–334. https://doi.org/10.2337/dc08-1625CrossRefPubMedPubMedCentral

40.

Gui Y, Pan Q, Chen X, Xu S, Luo X, Chen L (2017) The association between obesity related adipokines and risk of breast cancer: a meta-analysis. Oncotarget 8(43):75389–75399. https://doi.org/10.18632/oncotarget.17853CrossRefPubMedPubMedCentral

41.

Ogier V, Ziegler O, Méjean L, Nicolas JP, Stricker-Krongrad A (2002) Obesity is associated with decreasing levels of the circulating soluble leptin receptor in humans. Int J Obes 26(4):496–503. https://doi.org/10.1038/sj.ijo.0801951CrossRef

42.

Chan JL, Blüher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS (2002) Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes 51(7):2105–2112. https://doi.org/10.2337/diabetes.51.7.2105CrossRefPubMed

43.

Black MH, Shu YH, Wu J et al (2018) Longitudinal increases in adiposity contribute to worsening adipokine profile over time in Mexican Americans. Obesity (Silver Spring, MD) 26(4):703–712. https://doi.org/10.1002/oby.22128CrossRefPubMedPubMedCentral

44.

Rolland C, Hession M, Broom I (2011) Effect of weight loss on adipokine levels in obese patients. Diabetes Metab Syndr Obes Targets Ther 4:315. https://doi.org/10.2147/DMSO.S22788CrossRef

45.

Azuma K, Katsukawa F, Oguchi S et al (2003) Correlation between serum resistin level and adiposity in obese individuals. Obes Res 11(8):997–1001. https://doi.org/10.1038/oby.2003.137CrossRefPubMed

46.

Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I (2008) Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metab Clin Exp 57(4):494–501. https://doi.org/10.1016/j.metabol.2007.11.010CrossRefPubMed

47.

Gnacińska M, Małgorzewicz S, Łysiak-Szydłowska W, Sworczak K (2010) The serum profile of adipokines in overweight patients with metabolic syndrome. Endokrynol Pol 61(1):36–41PubMed

48.

Yun JE, Kimm H, Jo J, Jee SH (2010) Serum leptin is associated with metabolic syndrome in obese and nonobese Korean populations. Metab Clin Exp 59(3):424–429. https://doi.org/10.1016/j.metabol.2009.08.012CrossRefPubMed

49.

Zhao P, Xia N, Zhang H, Deng T (2020) The metabolic syndrome is a risk factor for breast cancer: a systematic review and meta-analysis. Obes Facts 13(4):384–396. https://doi.org/10.1159/000507554CrossRefPubMedPubMedCentral

50.

Lee CG, Carr MC, Murdoch SJ et al (2009) Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 94(4):1104–1110. https://doi.org/10.1210/jc.2008-0701CrossRefPubMedPubMedCentral

51.

Chu MC, Cosper P, Orio F, Carmina E, Lobo RA (2006) Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin. Am J Obstet Gynecol 194(1):100–104. https://doi.org/10.1016/j.ajog.2005.06.073CrossRefPubMed

52.

Pan XF, Wang L, Pan A (2021) Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 9(6):373–392. https://doi.org/10.1016/S2213-8587(21)00045-0CrossRefPubMed

53.

NCD Risk Factor Collaboration (NCD-RisC) (2016) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 387(10026):1377–1396. https://doi.org/10.1016/S0140-6736(16)30054-XCrossRef

Titel: Increases in BMI contribute to worsening inflammatory biomarkers related to breast cancer risk in women: a longitudinal study
verfasst von: Yu Hao
Jinyu Xiao
Ping Fu
Lanping Yan
Xunying Zhao
Xueyao Wu
Min Zhou
Xiaofan Zhang
Bin Xu
Xingyue Li
Zhenmi Liu
Chunxia Yang
Xin Wang
Lu Long
Xia Jiang
Jiaqiang Liao
Ben Zhang
Jiayuan Li
Publikationsdatum: 05.08.2023
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2023
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-023-07023-w

Retraction Note: Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways

Retraction Note

Effects of neighborhood disadvantage on cortisol and interviewer-rated anxiety symptoms in breast cancer patients initiating treatment

Original Laboratory Investigation

The impact of nurse navigation on timeliness to treatment for benign high-risk breast pathology

Epidemiology

Effect of neighborhood deprivation index on breast cancer survival in the United States

Open Access
Epidemiology

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

Open Access
Original Laboratory Investigation

Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study

Open Access
Preclinical study

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

15.01.2025
Melanom
Nachrichten

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Increases in BMI contribute to worsening inflammatory biomarkers related to breast cancer risk in women: a longitudinal study